Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluate the clinical utility of circulating tumor DNA (ctDNA) for dynamic recurrence risk and adjuvant ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Bin, Guo, Wei, Zhang, Fan, Lv, Fang, Ji, Ying, Peng, Yue, Chen, Xiaoxi, Bao, Hua, Xu, Yang, Shao, Yang, Tan, Fengwei, Xue, Qi, Gao, Shugeng, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605017/
https://www.ncbi.nlm.nih.gov/pubmed/34799585
http://dx.doi.org/10.1038/s41467-021-27022-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605017/
https://www.ncbi.nlm.nih.gov/pubmed/34799585
http://dx.doi.org/10.1038/s41467-021-27022-z

Ejemplares similares